FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1600-1601 June 13, 1996 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

In this issue of the Journal, Muto et al.¹ report a decrease in the incidence of second primary hepatocellular carcinomas in patients treated with polyprenoic acid, an acyclic retinoid, after the resection or ethanol ablation of small, solitary primary hepatocellular carcinomas. The rationale for this clinical trial was based on studies in animal models of hepatocarcinogenesis and hepatoma cell lines, which suggested that polyprenoic acid inhibits chemically induced or spontaneous hepatocarcinogenesis and suppresses cell growth and the production of alpha-fetoprotein in human hepatoma cell lines. Muto and colleagues, who have been studying retinoid derivatives for more than a decade, have . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Yang, C.-H. J., Cheng, A.-L., Decensi, A., Costa, A., Muto, Y., Moriwaki, H., Okuno, M. (1996). Polyprenoic Acid in Hepatocellular Carcinoma. NEJM 335: 1460-1462 [Full Text]